Stockscreener 앱 받기
1.61
9.04%
-0.16
시간 외 거래:
1.62
0.01
+0.62%
전일 마감가:
$1.77
열려 있는:
$1.76
하루 거래량:
429.54K
Relative Volume:
0.53
시가총액:
$171.64M
수익:
$45.44M
순이익/손실:
$-35.43M
주가수익비율:
-4.7353
EPS:
-0.34
순현금흐름:
$-25.39M
1주 성능:
+4.55%
1개월 성능:
+7.33%
6개월 성능:
-38.31%
1년 성능:
-57.52%
1일 변동 폭
$1.60
$1.79
1주일 범위
$1.53
$1.865
52주 변동 폭
$1.26
$5.20
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
MXCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.61 | 188.69M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
128.54 | 222.13B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
99.24 | 144.89B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
374.42 | 141.17B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.78 | 121.91B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
74.64 | 42.65B | 5.69B | 1.41B | 577.90M | 6.9828 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 개시 | Stephens | Overweight |
| 2023-11-29 | 개시 | Craig Hallum | Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-24 | 개시 | BTIG Research | Buy |
| 2021-08-24 | 개시 | Cowen | Outperform |
| 2021-08-24 | 개시 | Stephens | Overweight |
| 2021-08-24 | 개시 | Stifel | Buy |
| 2021-08-24 | 개시 | Wedbush | Outperform |
| 2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
Can MaxCyte Inc. stock deliver sustainable ROE2025 Stock Rankings & Reliable Entry Point Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Is MaxCyte Inc. stock a buy in volatile marketsEarnings Growth Summary & AI Driven Stock Movement Reports - newser.com
Predicting MaxCyte Inc. trend using moving averagesJuly 2025 Closing Moves & Fast Exit/Entry Strategy Plans - newser.com
Why MaxCyte Inc. stock remains a top recommendationWeekly Volume Report & Real-Time Market Sentiment Reports - newser.com
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Is MaxCyte Inc. trending in predictive chart modelsMarket Performance Report & Verified Stock Trade Ideas - newser.com
Will MaxCyte Inc. stock recover faster than peers2025 Earnings Impact & Daily Volume Surge Trade Alerts - newser.com
MaxCyte cuts 15% of global workforce, boosts core revenue guidance - MSN
MaxCyte announces 34% workforce reduction to cut costs - MSN
Will MaxCyte Inc. (MYE0) stock deliver stable dividendsRate Cut & Low Risk Growth Stock Ideas - newser.com
MaxCyte Inc. recovery potential after sell offPortfolio Profit Report & Daily Chart Pattern Signal Reports - newser.com
Real time social sentiment graph for MaxCyte Inc.Quarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Farther Finance Advisors LLC Raises Holdings in MaxCyte, Inc. $MXCT - Defense World
Is this a good reentry point in MaxCyte Inc.July 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Will MaxCyte Inc. (MYE0) stock see valuation expansion2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Applying big data sentiment scoring on MaxCyte Inc.July 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Market reaction to MaxCyte Inc.’s recent news2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Applying sector rotation models to MaxCyte Inc.July 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
How to use a screener to detect MaxCyte Inc. breakoutsJuly 2025 Update & High Accuracy Trade Alerts - newser.com
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | Oklahoma City NewsThe Oklahoman - FinancialContent
Q3 2025 Results on Nov 5 — MaxCyte to Release Financials After U.S. Market Close; Call 4:30 PM ET - Stock Titan
MaxCyte, Inc. Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - MarketScreener
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
MaxCyte Signs Strategic Platform License with Moonlight Bio | MXCT Stock News - Stock Titan
Intraday pattern recognizer results for MaxCyte Inc.Short Setup & Verified Swing Trading Watchlists - newser.com
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
What analysts say about MaxCyte Inc stockTrade Execution Strategies & The Best Picks Hiding in Plain Sight - earlytimes.in
Tick level data insight on MaxCyte Inc. volatilityJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.73%
0.04%
자본화:
|
볼륨(24시간):